Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular

Set Alert for Cardiovascular

D-Day Approaches For Bayer’s Asundexian Phase III Plans

With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.

Sales & Earnings Cardiovascular

AstraZeneca’s Farxiga DELIVERs With Fresh Heart Failure Data

AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.

Cardiovascular Clinical Trials

BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use

Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label. 

Launches Cardiovascular

AstraZeneca’s Farxiga Flies Across $1bn Barrier

First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.

Coronavirus COVID-19 Sales & Earnings

Forcefield Therapeutics Launched With ‘Gamechanger’ Goal For Post-MI Therapy

The newly launched biotech has a novel platform for discovering protective tissue factors and turning them into therapies,with heart failure prevention its first target.

Companies Cardiovascular

Novartis’s Kesimpta Already A Big Earner But Leqvio Is Slow Burner

Novartis’s multiple sclerosis treatment Kesimpta has shot out of the gates and bidding fair to contribute generously to the firm’s coffers, while new cholesterol drug Leqvio struggles, Q1 results show.

Commercial Sales & Earnings

Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity

On the way to seeking approval for istaroxime in acute heart failure, Windtree became convinced that early cardiogenic shock could be a good get-to-market strategy for its blood pressure-improving drug.

Clinical Trials Drug Approval Standards

Boehringer Pharma Chief Confident Of Continued Success For Jardiance

Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.

Business Strategies Leadership

Merck & Co Maps Out Route To $10bn Cardiovascular Franchise

The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.

Companies Innovation

AstraZeneca and Ionis Think They Have A Best-In-Class PCSK9 Challenger To Novartis’s Leqvio

AstraZeneca and Ionis believe they have a potential best-in-class PCSK9 inhibitor, but the product will have to impress in forthcoming pivotal trials to catch up with Novartis’s Leqvio.

Companies Clinical Trials

Cytokinetics Rocked By Another Omecamtiv Setback

The biotech’s cardiology asset has failed an advanced study focused on exercise capacity in heart failure, having underwhelmed observers with past data, but hope remains that the LVEF subset could be a saving grace.

Clinical Trials Cardiovascular

Bristol’s Mavacamten Shows Consistent Efficacy, Safe Use In Obstructive HCM At ACC

Long-term results from the EXPLORER-HCM extension study are consistent with the pivotal trial in obstructive hypertrophic cardiomyopathy, while data from VALOR may support a supplemental filing.

Cardiovascular Clinical Trials
See All
UsernamePublicRestriction

Register